Literature DB >> 19102497

[Aberrant expression of sperm protein 17 enhances migration of ovarian cancer cell line HO-8910].

Qun Liu1, Fang-Qiu Li, Yan-Ling Han, Li-Kui Wang, Ya-Yi Hou.   

Abstract

OBJECTIVE: To explore the effects of aberrant expression of sperm protein 17 (Sp17) on the migration of the ovarian cancer cell line HO-8910.
METHODS: The recombinant plasmid pEGFP-Sp17 containing Sp17 and enhanced green fluorescent protein gene was transfected into the human ovarian cancer cell line HO-8910 with Lipofectamine 2000. The expression of Sp17 was examined by RT-PCR and Western blot, and the cell migratory capability detected by Transwell chamber assays.
RESULTS: Sp17 was expressed as a fusion protein with EGFP after transfected. There was a significant difference in the migratory cell number of the transfected and the control cells (156.6 +/- 14.9/HP vs 39.3 +/- 8.53/HP, P < 0.05).
CONCLUSION: The aberrant expression of Sp17 greatly enhances the migration of ovarian cancer cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19102497

Source DB:  PubMed          Journal:  Zhonghua Nan Ke Xue        ISSN: 1009-3591


  3 in total

1.  Anti-Sp17 monoclonal antibody with antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activities against human ovarian cancer cells.

Authors:  Jia-xi Song; Wang-li Cao; Fang-qiu Li; Li-ning Shi; Xuan Jia
Journal:  Med Oncol       Date:  2011-12-24       Impact factor: 3.064

2.  Anti-Sp17 monoclonal antibody-doxorubicin conjugates as molecularly targeted chemotherapy for ovarian carcinoma.

Authors:  Jia-Xi Song; Fang-Qiu Li; Wang-Li Cao; Xuan Jia; Li-Ning Shi; Jing-Fen Lu; Chun-Fang Ma; Qian-Qian Kong
Journal:  Target Oncol       Date:  2013-08-14       Impact factor: 4.493

3.  Sperm Protein Antigen 17 Expression Correlates With Lymph Node Metastasis and Worse Overall Survival in Patients With Breast Cancer.

Authors:  Yu-Ting Zhou; Juan-Juan Qiu; Yao Wang; Peng-Cheng Liu; Qing Lv; Zheng-Gui Du
Journal:  Front Oncol       Date:  2019-07-31       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.